INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2019

Two years after Microbiota Transfer Therapy, participants with ASD maintained GI improvements, showed further autism symptom gains, and sustained gut changes.

Researchers conducted a two-year follow-up of 18 participants with Autism Spectrum Disorders who previously completed an open-label trial of Microbiota Transfer Therapy (MTT) combining antibiotics, bowel cleanse, acid suppressant, and fecal microbiota transplant. Most improvements in gastrointestinal symptoms were maintained, and autism-related symptoms improved further two years after treatment ended. Important gut microbiota changes persisted, including significant increases in bacterial diversity and relative abundances of Bifidobacteria and Prevotella.

Study type
Two-year follow-up of an open-label clinical trial
Who was studied
18 participants with Autism Spectrum Disorders (ASD) who completed Microbiota Transfer Therapy
What was measured
Gastrointestinal symptoms, autism-related symptoms, and gut microbiota changes

THE PAPER

Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota.

Kang DW, Adams JB, Coleman DM, Pollard EL, Maldonado J, McDonough-Means S, Caporaso JG, Krajmalnik-Brown R. Sci Rep, 2019.

PubMed 30967657 ↗DOI 10.1186/s40168-018-0470-z ↗

Gut & microbiomeBrain & mood

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.